Glioblastoma broadband power as a longitudinal biomarker for tumor progression

Glioblastoma broadband power as a longitudinal biomarker for tumor progression - GOALS2

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54202

Enrollment

100

Registered

2021-07-28

Start date

2021-12-08

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumor glioblastoma

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: (1) age > 17 years, (2) histopathologically confirmed glioma, (3) eligible to start radiotherapy

Exclusion criteria

Exclusion criteria: (1) psychiatric disease or symptoms at the time of inclusion, (2) other comorbidities of the central nervous system, particularly cerebrovascular accidents, multiple sclerosis, Alzheimer*s disease, (3) insufficient mastery of the Dutch language, (4) inability to communicate adequately. For the additional MRI sequences, an exclusion criterium is incompatibility with MRI.

Design outcomes

Primary

Measure	Time frame
(1) MEG/EEG brain activity at different timepoints during the disease, and (2) radiological and clinical markers of tumor growth	—

Secondary

Measure	Time frame
(1) chemical exchange saturation transfer (CEST) MRI and resting-state functional MRI (rsfMRI) at a number of timepoints	—

Countries

Netherlands

Outcome results